Literature DB >> 14978639

Medical management of fecal incontinence.

Yolanda Scarlett1.   

Abstract

Diarrhea and constipation are known risk factors for fecal incontinence. This report reviews how to diagnose and medically treat patients with chronic diarrhea, chronic constipation with overflow incontinence, and incontinence resulting from rectal mucosal prolapse secondary to hemorrhoids. Antidiarrheal agents (including loperamide, diphenoxylate, and difenoxin) and the tricyclic antidepressant amitriptyline improve continence in patients with diarrhea-associated incontinence. Other antidiarrheal agents are under investigation. The mechanism is believed to be decreased intestinal motility and stool frequency resulting in more formed stools. Increases in anal canal resting pressure may also contribute to improvement in continence. Adverse effects are constipation from excessive use. In addition to antidiarrheal drugs, fiber supplements may improve incontinence associated with diarrhea. Transient, benign cases of constipation usually respond to increasing fluid intake and dietary fiber, improving mobility, or eliminating the concurrent use of constipating drugs. For mild to moderate constipation, bulking agents, laxatives, and stool softeners are used cautiously so as not to excessively loosen stools and exacerbate anal incontinence. Laxatives have been shown to improve continence, possibly through the mechanism of eliminating fecal impaction. Prolapsing hemorrhoids may partially obstruct defecation and cause soilage from the passage of fecal material, mucus, or blood. With endoscopic banding, a ligator is attached to an endoscope and a tight band is placed around the enlarged vein, causing the hemorrhoid to thrombose.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14978639     DOI: 10.1053/j.gastro.2003.10.007

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  14 in total

Review 1.  Investigation and treatment of faecal incontinence.

Authors:  S Maslekar; A Gardiner; C Maklin; G S Duthie
Journal:  Postgrad Med J       Date:  2006-06       Impact factor: 2.401

2.  Office-based management of fecal incontinence.

Authors:  Vanessa C Costilla; Amy E Foxx-Orenstein; Anita P Mayer; Michael D Crowell
Journal:  Gastroenterol Hepatol (N Y)       Date:  2013-07

Review 3.  Medical management of fecal incontinence in challenging populations: a review.

Authors:  David Lee; Gaurav Arora
Journal:  Clin Colon Rectal Surg       Date:  2014-09

4.  Management of patients with rectal prolapse: the 2017 Dutch guidelines.

Authors:  E M van der Schans; T J C Paulides; N A Wijffels; E C J Consten
Journal:  Tech Coloproctol       Date:  2018-08-11       Impact factor: 3.781

5.  The effects of clonidine on symptoms and anorectal sensorimotor function in women with faecal incontinence.

Authors:  A E Bharucha; B M Seide; A R Zinsmeister
Journal:  Aliment Pharmacol Ther       Date:  2010-09       Impact factor: 8.171

6.  Treatment of functional diarrhea.

Authors:  Evan S Dellon; Yehuda Ringel
Journal:  Curr Treat Options Gastroenterol       Date:  2006-07

7.  A cross-sectional survey of the relationship between fecal incontinence and constipation.

Authors:  Eddie H M Sze; C Debra Barker; Gerry Hobbs
Journal:  Int Urogynecol J       Date:  2012-06-20       Impact factor: 2.894

8.  Local transdermal delivery of phenylephrine to the anal sphincter muscle using microneedles.

Authors:  Changyoon Baek; MeeRee Han; Junhong Min; Mark R Prausnitz; Jung-Hwan Park; Jung Ho Park
Journal:  J Control Release       Date:  2011-05-07       Impact factor: 9.776

9.  Fecal incontinence in an inpatient population: a not uncommon finding.

Authors:  Brian T Hughes; Pavan Chepyala; Shane Hendon; Michael D Crowell; Kevin W Olden
Journal:  Dig Dis Sci       Date:  2008-12-05       Impact factor: 3.199

10.  Antidiarrheal Effect of DLBS1Y62, a Bioactive Fraction of Uncaria gambir Roxb. Dried Sap Extract, in Wistar Rats.

Authors:  Dicky A Wibowo; Florensia Nailufar; Raymond R Tjandrawinata
Journal:  J Exp Pharmacol       Date:  2021-07-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.